Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹13 Cr.
Stock P/E
-7.8
P/B
0.6
Current Price
₹12.7
Book Value
₹ 21.6
Face Value
10
52W High
₹25.8
52W Low
₹ 9
Dividend Yield
—

Global Longlife Hosp Overview

Business

Global Longlife Hospital and Research Ltd. (GLHRL) operates within the Hospital & Healthcare Services sector in India. Its core business involves the direct provision of medical and surgical care to patients. This includes operating multi-specialty or super-specialty hospitals, offering services such as outpatient consultations, inpatient care, emergency services, surgical procedures, diagnostic tests (pathology, radiology), pharmacy services, and rehabilitation. The company generates revenue primarily through fees charged to patients for these services, which may be paid directly, through health insurance providers, or via corporate tie-ups.

Revenue Mix

While specific figures for GLHRL are unavailable, a typical hospital's revenue mix is generally segmented as follows:

Inpatient Services: Revenue from patient admissions, room charges, surgical procedures, and intensive care units. This usually forms the largest portion of revenue.

Outpatient Services: Consultations, day-care procedures, and minor treatments.

Diagnostics: Fees from laboratory tests and imaging services (X-rays, MRI, CT scans).

Pharmacy: Sales of medicines and medical supplies.

Other Services: Emergency room charges, health check-ups, and rehabilitation services.

The exact contribution of each segment would depend on the hospital's specialization, scale, and patient mix.

Industry

The Indian Hospital & Healthcare Services industry is characterized by significant growth, driven by increasing demand for quality healthcare. It is highly competitive, with a mix of large corporate hospital chains, regional players, single hospitals, and government-run facilities. Corporate hospitals often differentiate themselves through advanced technology, specialized medical talent, and brand reputation. Without specific details on GLHRL's scale or market presence, it is difficult to precisely position it. It likely operates as a multi-specialty hospital aiming to cater to local or regional demand for a range of medical services, competing with both larger chains for complex cases and smaller facilities for routine care.

MOAT

For a hospital, durable competitive advantages can be challenging to establish but typically revolve around:

Brand and Reputation: A strong reputation for clinical excellence, patient outcomes, and ethical practices can attract and retain patients.

Specialized Expertise/Centers of Excellence: Leadership in specific medical fields (e.g., cardiology, oncology) attracts patients seeking specialized care.

Doctor Relationships: Ability to attract and retain highly reputed doctors and medical staff.

Location Advantage: Strategic placement in densely populated areas or regions with underserved healthcare needs.

Scale: Larger networks can achieve economies of scale in procurement and technology adoption.

Without specific information, it's unclear if GLHRL possesses a significant moat. Building a strong brand and clinical reputation in a competitive market requires consistent investment in quality, talent, and patient experience over many years.

Growth Drivers

Key factors that can drive growth for GLHRL over the next 3-5 years include:

Rising Healthcare Expenditure: Increasing disposable incomes and greater health awareness among the Indian population.

Demographic Shifts: A growing and aging population leading to higher incidence of chronic and lifestyle diseases.

Government Initiatives: Schemes like Ayushman Bharat (PM-JAY) increasing access to insurance coverage and private healthcare.

Medical Tourism: Attracting international patients seeking quality and affordable treatment.

Expansion & Specialization: Opening new facilities, expanding bed capacity, or developing new super-specialty services to tap into unmet demand.

Technological Adoption: Investing in advanced medical technology and digital health solutions to improve outcomes and efficiency.

Risks

Regulatory & Pricing Risks: Government interventions in pricing for medical procedures, drug costs, or changes in healthcare policies.

Talent Scarcity & Retention: Difficulty in attracting, retaining, and managing highly skilled doctors, nurses, and paramedical staff.

Intense Competition: Pressure from established large hospital chains and new entrants, leading to pricing pressure and market share erosion.

High Capital Expenditure: Hospitals are capital-intensive businesses requiring continuous investment in infrastructure, equipment, and technology.

Medical Malpractice & Litigation: Risks associated with adverse patient outcomes, leading to legal challenges and reputational damage.

Economic Downturns: Reduced affordability for elective procedures or private healthcare services during economic slowdowns.

Infection Control & Public Health Crises: Outbreaks can strain resources, deter patients, and necessitate costly preventative measures.

Management & Ownership

In India, many companies, especially mid-sized ones, are promoter-led. Typically, the promoters (founding families or individuals) hold a significant stake and are actively involved in the management. Without specific information, it's difficult to comment on the quality of GLHRL's management or the precise ownership structure. Strong corporate governance, strategic vision, and operational execution skills are critical for success in the healthcare sector.

Outlook

The outlook for GLHRL is a blend of opportunities and challenges. The Indian healthcare market presents significant tailwinds from demographic trends, increasing health awareness, and rising incomes, suggesting a long runway for growth. Hospitals that can deliver high-quality, patient-centric care, build a strong brand reputation, and manage costs effectively are well-positioned to benefit. However, GLHRL operates in a highly competitive and capital-intensive industry. Its success will depend heavily on its ability to attract and retain top medical talent, differentiate its services, navigate evolving regulatory landscapes, control operational costs, and execute its expansion strategies effectively. Companies in this sector also face constant pressure from pricing competition and the need for continuous technological upgrades.

Global Longlife Hosp Share Price

Live · BSE · Inception: 2012
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Global Longlife Hosp Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Global Longlife Hosp Profit & Loss

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 35 34 33 33 24 14 1 0
Other Income 0 0 0 0 0 0 5 0
Total Income 35 34 33 33 24 14 6 0
Total Expenditure 28 30 27 25 19 14 5 1
Operating Profit 7 4 5 8 4 -0 1 -1
Interest 2 2 2 2 0 1 0 0
Depreciation 2 2 1 1 1 1 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0
Profit Before Tax 3 -1 2 6 3 -2 0 -1
Provision for Tax 1 -0 -0 2 1 -0 -0 1
Profit After Tax 1 -1 2 4 2 -2 0 -2
Adjustments 0 0 0 0 0 0 0 0
Profit After Adjustments 1 -1 2 4 2 -2 0 -2
Adjusted Earnings Per Share 0 0 2.9 5.1 1.7 -2.1 0.2 -1.6

Global Longlife Hosp Balance Sheet

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 12 11 14 17 64 26 27 24
Minority's Interest 0 0 0 0 0 0 0 0
Borrowings 18 17 13 3 4 3 0 0
Other Non-Current Liabilities -3 -3 -3 -2 -2 -2 -2 -2
Total Current Liabilities 13 13 10 14 8 12 0 0
Total Liabilities 40 39 33 31 74 40 24 21
Fixed Assets 20 19 17 17 17 17 0 0
Other Non-Current Assets 5 4 0 0 21 16 0 0
Total Current Assets 15 16 12 11 34 4 23 20
Total Assets 40 39 33 31 74 40 24 21

Global Longlife Hosp Cash Flow

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 0 0 1 0 0 4 0 21
Cash Flow from Operating Activities 5 4 7 9 -40 -5 12 -5
Cash Flow from Investing Activities -0 -0 0 0 -2 -1 22 0
Cash Flow from Financing Activities -5 -3 -7 -10 46 3 -13 -0
Net Cash Inflow / Outflow 0 1 -0 -0 3 -3 21 -4
Closing Cash & Cash Equivalent 0 1 0 0 4 0 21 17

Global Longlife Hosp Ratios

# Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 0 0 2.92 5.11 1.74 -2.08 0.19 -1.64
CEPS(Rs) 5.03 1.8 4.79 6.74 2.85 -0.89 0.65 -1.64
DPS(Rs) 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 0 0 14.46 19.98 58.94 22.62 23.78 21.56
Core EBITDA Margin(%) 19.53 10.1 16.62 25.09 17.31 -2.25 -717.06 0
EBIT Margin(%) 13.84 4.1 12.82 22.3 13.36 -11.03 68.35 0
Pre Tax Margin(%) 7.78 -3.17 5.37 17.4 11.52 -16.77 17.18 0
PAT Margin (%) 3.95 -2.57 6.26 10.89 7.78 -16.19 34.42 0
Cash Profit Margin (%) 10.18 3.77 10.25 14.38 12.74 -6.94 117.89 0
ROA(%) 3.4 -2.19 5.72 11.1 3.47 -3.86 0.62 -7.49
ROE(%) 11.05 -7.23 18.94 29.65 4.82 -5.11 0.82 -7.22
ROCE(%) 12.09 3.69 13.49 29.36 6.69 -2.77 1.28 -4.15
Receivable days 91.86 81.4 78.74 93.14 144.47 157.23 716.69 0
Inventory Days 21.33 22.92 16.78 9.43 13.19 16.92 0 0
Payable days 230.64 294.78 184.77 381.81 235.49 578.77 1068.12 0
PER(x) 0 0 0 0 25.73 0 100.21 0
Price/Book(x) 0 0 0 0 0.76 1.73 0.8 0.63
Dividend Yield(%) 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.98 0.87 0.72 0.47 2.24 3.95 -2.74 0
EV/Core EBITDA(x) 4.86 8.35 4.29 1.83 12.24 -221.94 -1.81 2.71
Net Sales Growth(%) 0 -2.88 -2.51 0.34 -28.38 -42.5 -95.73 -100
EBIT Growth(%) 0 -71.25 205.02 74.56 -57.1 -147.47 126.47 -350.3
PAT Growth(%) 0 -163.19 337.36 74.59 -48.87 -219.73 109.08 -965.37
EPS Growth(%) 0 0 337.36 74.59 -65.91 -219.73 109.08 -965.54
Debt/Equity(x) 2.2 2.05 1.68 0.62 0.15 0.54 0 0
Current Ratio(x) 1.17 1.18 1.14 0.82 4.28 0.32 405.69 1691.15
Quick Ratio(x) 1.02 1.02 1.06 0.76 4.17 0.28 405.69 1691.15
Interest Cover(x) 2.28 0.56 1.72 4.55 7.27 -1.92 1.34 -3292.33
Total Debt/Mcap(x) 0 0 0 0 0.2 0.31 0 0

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -100% -100% -100% —
Operating Profit CAGR -200% 0% 0% —
PAT CAGR — 0% 0% —
Share Price CAGR -48% -34% — —
ROE Average -7% -4% +5% +6%
ROCE Average -4% -2% +6% +7%

Global Longlife Hosp Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 22.88 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 77.12 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 54.2954.2954.2954.2954.2954.955.135.4422.8822.88
FII 0000000000
DII 0000000000
Public 45.7145.7145.7145.7145.7145.144.964.5677.1277.12
Others 0000000000
Total 100100100100100100100100100100

Global Longlife Hosp Peer Comparison

Hospital & Healthcare Services Edit Columns

Global Longlife Hosp Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Global Longlife Hosp Pros & Cons

Pros

  • Stock is trading at 0.6 times its book value
  • Debtor days have improved from 1068.12 to 0days.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 22.88%.
  • Company has a low return on equity of -4% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp